The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

CHICAGO (Reuters) - Two standard treatments for hepatitis C work equally well at knocking down the virus for most patients, U.S. researchers reported on Wednesday. The findings, from a 3,000-patient ...

(Reuters) - A trio of oral medicines from Abbott Laboratories Inc to treat hepatitis C produced unprecedented cure rates in patients who had failed to benefit from standard treatment, as well as very ...

The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C.

There's a new drug regimen being touted as a potential cure for a dangerous liver virus that causes hepatitis C. But it costs $84,000 -- or $1,000 a pill. And that price tag is prompting outrage from ...

It’s been almost a year since federal regulators approved a new hepatitis C treatment that costs about $1,000 per pill. But time hasn’t done much to ease concerns of state officials who worry about ...

Pharmasset, Inc. has received fast-track designation from the U.S. Food and Drug Administration for R7128 for the treatment of chronic hepatitis C virus infection.Pharmasset, Inc. (Nasdaq: VRUS) has ...

Any national campaign to eliminate hepatitis C, an insidious virus that kills tens of thousands of Americans a year, would almost certainly involve prisons. One in 7 state inmates are believed to be ...

WHO releases new framework to tackle drug resistance to HIV, hepatitis B and C, and STIs: Geneva Thursday, November 27, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) h ...

NEW YORK (AP) — Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure. The New York company said ...

Novartis agreed to pay as much as $440 million for the rights to an experimental drug against hepatitis C, joining Foster City's Gilead Sciences and Bristol-Myers Squibb in seeking deals to gain ...